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disease and Alzheimer disease, were evident in all subjects. 
We evaluated areas that may be relevant to rDP separately 
from those affected by the comorbid conditions. Anatomi-
cal areas identified as potential targets of I758S mutation 
were globus pallidus, subthalamic nucleus, red nucleus, 
inferior olivary nucleus, cerebellar Purkinje and granule 
cell layers, and dentate nucleus. Involvement of subcortical 
white matter tracts was also evident. Furthermore, in the 
spinal cord, a loss of dorsal column fibers was noted. This 
study has identified rDP-associated pathology in neuronal 
populations, which are part of complex motor and sensory 
loops. Their involvement would cause an interruption of 
cerebral and cerebellar connections which are essential for 
maintenance of motor control.
Keywords  DYT12 · rDP · rapid-onset dystonia-
parkinsonism · Neuropathology
Abstract  rapid-onset dystonia-parkinsonism (rDP) 
is a movement disorder associated with mutations in the 
ATP1A3 gene. Signs and symptoms of rDP commonly 
occur in adolescence or early adulthood and can be trig-
gered by physical or psychological stress. Mutations in 
ATP1A3 are also associated with alternating hemiplegia of 
childhood (AHC). The neuropathologic substrate of these 
conditions is unknown. The central nervous system of four 
siblings, three affected by rDP and one asymptomatic, all 
carrying the I758S mutation in the ATP1A3 gene, was ana-
lyzed. This neuropathologic study is the first carried out 
in ATP1A3 mutation carriers, whether affected by rDP or 
AHC. Symptoms began in the third decade of life for two 
subjects and in the fifth for another. The present investiga-
tion aimed at identifying, in mutation carriers, anatomical 
areas potentially affected and contributing to rDP patho-
genesis. Comorbid conditions, including cerebrovascular 
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Introduction
rapid-onset dystonia-parkinsonism (rDP) is a rare disease 
associated with mutations in the ATP1A3 gene [3, 6, 11, 19, 
30, 35, 39], located on chromosome 19. rDP is inherited 
with an autosomal dominant pattern and incomplete pen-
etrance. recently, ATP1A3 mutations have been shown to 
be also associated with alternating hemiplegia of childhood 
(AHC), which is characterized by early paroxysmal events, 
developmental delay and later dystonia, ataxia, choreoathe-
tosis and seizures [26]. The Na+/K+-ATPase alpha subunit 
3 (ATP1A3) is one of the essential components that main-
tain the proper sodium and potassium gradients across cell 
membranes [11].
epidemiological data related to rDP and AHC are lim-
ited and there is not a recently published report summariz-
ing the known data. The number of individuals affected by 
rDP is estimated to be 75 worldwide (A.B., personal com-
munication) while AHC is estimated to affect one person in 
one million [25]. rDP and AHC are associated to ATP1A3 
gene mutations. The number of mutations is 14 for rDP 
[3, 6, 11, 19, 30, 35, 39] and 37 for AHC [12, 14, 18, 30–
32]. Both rDP and AHC may be associated with de novo 
mutations.
The clinical phenotype of rDP is typically character-
ized by abrupt onset of dysarthria, dysphagia, limb dystonia 
with bradykinesia, and postural instability [13]. In a study 
of 29 patients with mutations in the ATP1A3 gene, 76 % 
had onset of motor symptoms before the age of 25 years 
[7]. Other symptoms, including anxiety, cognitive impair-
ment [10] and psychosis, have recently been reported [2, 7]. 
The reported age range for onset of rDP is 9 months [6] 
to 59 years [2]. Most patients present with speech (38 %) 
and arm (5 %) dystonia; however, leg involvement alone has 
also been reported [6, 36]. Onset of symptoms in rDP has 
often been related to physical and psychological stresses. 
The former includes running, fever, childbirth, and alcohol 
abuse. recognized symptom onset occurs shortly following 
one of these specific events. Some at risk individuals have 
been exposed to similar triggers, but never developed symp-
toms of the disease. Most patients with rDP have persis-
tent symptoms over time; however, some individuals have 
reported an additional episode of abrupt worsening of symp-
toms. Fluctuating motor symptoms have been observed in 
the two infants with rDP, previously reported [6].
Structural imaging has provided some insight into cen-
tral nervous system areas that might be potentially affected 
in rDP. In fact, Whitlow and colleagues [37] studied three 
subjects carrying mutations in ATP1A3 gene and found sig-
nificant gray matter volume and fractional anisotropy (FA) 
decreases in the parahippocampal gyrus and dentate nucleus, 
unilaterally. Fractional anisotropy was also decreased in 
the superior cerebellar peduncles, thalami, basal ganglia 
(caudate nucleus, putamen, and globus pallidus), internal and 
external capsules, and corpus callosum [37].
The present study details the neuropathologic and the 
molecular genetic findings in four siblings, three affected 
and one asymptomatic, all carrying the I758S mutation in the 
ATP1A3 gene. These subjects are members of a large fam-
ily originally reported by Dobyns et al. [13]. The mutation 
in members of this family was originally reported by de Car-
valho-Aguiar [11]. The clinical phenotype associated with the 
I758S mutation is similar to that seen in individuals affected 
by rDP but carrying different ATP1A3 gene mutations.
In consideration of the fact that in the individuals 
described in this study, rDP manifests itself early in life 
and has a life-long duration, identifying the anatomical 
abnormality and related histopathology may be challeng-
ing due to the fact that the neuropathologic studies are 
being carried out many years since the beginning of symp-
tomatology. Therefore, we made an effort to distinguish 
the alterations of gray and white matter structures that we 
hypothesize to be underlying rDP, from vascular and neu-
rodegenerative pathology, associated with aging and Alz-
heimer disease. This study is the first describing anatomical 
alterations in ATP1A3 mutation carriers.
Methods
Clinical assessments
The pedigree, to which the four individuals that are the 
object of the present study belong, was included in the first 
paper describing rDP [13]. In that study, one family mem-
ber, later found to carry the I758S mutation in the ATP1A3 
gene, was described. That individual and the additional 
three siblings, all mutation carriers, were subsequently 
examined over the following 25 years. each subject signed 
an IrB-approved Wake Forest School of Medicine Consent. 
Furthermore, all individuals signed the appropriate autopsy 
consent forms several years prior to their death. The clini-
cal assessment carried out by A.B. included a standardized 
patient history questionnaire covering rDP antecedent 
symptoms, triggers, motor and non-motor symptoms, and a 
standardized videotaped neurologic examination including 
the Unified Parkinson’s Disease rating Scale [24] and the 
Burke–Fahn–Marsden [8] dystonia rating scale. The videos 
and scales were blindly reviewed by an expert in dystonia 
(M.S.).
Psychiatric and cognitive testing
Formal psychiatric and cognitive evaluations were per-
formed on individuals capable of participating. These eval-
uations have been described in prior reports [7, 10].83 Acta Neuropathol (2014) 128:81–98 
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Neuropathologic methods
Neuropathologic studies were carried out on all four sub-
jects. Table 1 includes information about the four subjects’ 
(case 1, 2, 3, 4) gender, age of onset, mutation status, age at 
death, post-mortem interval, brain weight, Alzheimer disease 
changes and Apolipoprotein E (APOE) alleles. In addition, 
neuropathologic analysis was carried out on the brain of 16 
controls cases (Supplementary Table 1). These controls were 
selected on the basis of age and comorbid conditions.
Autopsy from all four subjects and controls was limited 
to the brain and spinal cord; cases 1 and 3 were harvested 
at Indiana University and cases 2 and 4 were harvested at 
other institutions. At the time of autopsy, the brains of case 
1, 3, 4 and the controls were hemisected along the mid-sag-
ittal plane. The left hemibrain and spinal cord were fixed 
in formalin and the right hemibrain was sliced, frozen, 
and stored at −70 °C. For case 2, the anterior part of the 
frontal lobe (bilaterally), the cerebellum, and the brainstem 
were frozen and stored at −70 °C; the remaining portions, 
including the spinal cord, were fixed in formalin.
Following fixation in a 10 % formalin solution, brain 
tissue samples listed in Table 2 were dehydrated in graded 
alcohols, cleared in xylene, and embedded in paraffin 
(see Fig. 1 for summary of tissue blocks obtained). eight-
micrometer-thick sections from the brain areas listed in 
Table  2 were stained with the histological and immuno-
histochemical methods described below. Hematoxylin and 
eosin (H&e) and luxol fast blue with hematoxylin & eosin 
(lFB-H&e) were used to survey gray and white matter 
for neuronal losses, gliosis, inflammatory changes, vascu-
lar pathology, and other possible pathologic lesions. Peri-
odic acid–Schiff (PAS) was used to rule out the presence of 
PAS-positive cellular or extracellular deposits. Heidenhain-
Woelcke was used to determine whether a loss of myelin or 
myelinated fibers was detectable. Bodian silver was selected 
to analyze neurons and their processes for the presence of 
abnormal fibrillar structures. Thioflavin S method was used 
to visualize amyloid deposits and neurofibrillary tangles. 
Neurodegenerative pathology was analyzed using antibod-
ies raised against amyloid beta (Aβ) (21F12), tau (AT8), 
glial fibrillary acidic protein (gFAP), α-synuclein [28], 
phosphorylated TDP-43 and ubiquitin. In the cerebellum, 
synaptophysin was used to detect possible synaptic losses 
while calbindin [9] was mainly used to investigate the status 
of the Purkinje cell somata and that of the dendrites in the 
molecular layer and axons throughout their course.
The signal from polyclonal antibodies was visualized 
using avidin–biotin, with goat anti-rabbit immunoglobu-
lin as the secondary antibody, followed by horseradish 
peroxidase-conjugated streptavidin and the chromogens 
diaminobenzidine or tetramethylbenzidine. The signal from 
monoclonal antibodies was detected using avidin–biotin, 
with goat anti-mouse immunoglobulin as the secondary 
antibody, followed by alkaline phosphatase-conjugated 
streptavidin and the chromogen diaminobenzidine or tetra-
methylbenzidine. Immunohistochemical sections were 
counterstained with hematoxylin.
Immunofluorescence in the cerebellum of the sympto-
matic mutation carriers, non-symptomatic mutation carrier, 
and controls was carried out. Slides were deparaffinized 
through graded xylenes, and antigen retrieval was performed 
with hot 10 mM Tris base and 1 mM disodium eDTA pH 
9.0 at 60 °C for 10 min. Slides were incubated with anti-
body as above, except that incubation with primary antibody 
(rabbit antibody from Santa Cruz Biotechnology, sc-16052, 
C-16, against Na,K-ATPase alpha3) was for 72 h. After 
washing, incubation with Alexa dye-conjugated fluorescent 
antibodies (life Technologies) was for 2 h, followed by 
additional washes. Fluorescence was evaluated with a Zeiss 
lSM 5 Pascal laser confocal microscope with the Zeiss 
rgB vario laser module of argon laser (458/488/514 nm) 
and two helium–neon lasers (543 and 633 nm).
In the four cases, we also obtained coronal sections of 
cerebral hemispheres as well as parasagittal sections of the 
cerebellum in three of the cases, to analyze in greater detail 
the gray and white matter pathology. Sections were stained 
using lFB-H&e as well as immunolabeled using antibod-
ies against gFAP and Thioflavin S. Coronal sections of the 
cerebral hemisphere were not obtained in the 16 controls.
Three investigators trained in anatomy and neuropa-
thology (AO, MH, Bg) carried out a survey of anatomical 
structures, independently, and reached a consensus. A semi-
quantitative analysis was carried out using a leica DMlB 
Table 1   Demographic information for each subject
* The brain weight of case 2 is an estimate
Case 
number
Sex Age of  
onset
Age at 
death
Affected 
(Y/N)
Mutation 
carrier
PMI (h) Brain  
weight (g)
Alzheimer Disease 
changes (A, B, C)
APOe
1 F 28 81 Yes Yes 9.0 1,144 3, 2 ,1 33
2 F 25 and 42 82 Yes Yes 12.0 1,128* 3, 2, 2 33
3 F n/a 87 No Yes 9.0 1,076 3, 2, 3 33
4 M 45 85 Yes Yes 5.0 1,226 3, 2, 2 2384   Acta Neuropathol (2014) 128:81–98
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microscope (leica Wetzlar, germany), from frontal cortex, 
cingulate cortex, temporal cortex, parietal cortex, insular 
cortex, occipital cortex, amygdala, hippocampus, subicu-
lum, parahippocampus, caudate nucleus, putamen, globus 
pallidus, thalamus, cerebellar hemisphere, dentate nucleus, 
substantia nigra, locus coeruleus, basis pontis, inferior 
olivary nucleus, and spinal cord. The severity of neuronal 
loss, gliosis, amyloid plaques, neurofibrillary tangles, and 
tau-immunoreactive neurons was evaluated using a subjec-
tive scale: none = 0, mild = 1 (+), moderate = 2 (++) 
and severe = 3 (+++). In view of the presence of Alzhei-
mer changes, we classified each case according to criteria 
of CerAD [22], Braak staging [5], and NIA-AA [17, 23].
The Atlas of the Human Brain 3rd edition [21] was 
adapted to map the loss of neurons, gliosis, and type of 
deposited protein (Aβ plaques, and neurofibrillary tangles) 
changes in the anatomical regions of interest.
Molecular genetic analysis
To detect the presence of the I758S mutation in the brain 
of the four siblings, DNA was extracted from samples of 
frozen cerebellum. Qiagen DNeasy Blood and Tissue Kit 
was used to isolate the DNA according to manufacturer’s 
instructions. PCr amplification of exon 17 of the ATP1A3 
gene was performed using primers and conditions specified 
previously [11], and the mutation was confirmed by Sanger 
sequencing. DNA was extracted from frozen tissue using 
standard procedures. APOE genotypes were determined by 
restriction enzyme digestion of amplified products [16].
Fig. 1   a–h The brain areas from which samples for neuropathologic 
studies were obtained. Brain areas highlighted in (a–h) (blue or yel-
low) represent the following regions: anterior cingulate gyrus, supe-
rior frontal gyrus, middle frontal gyrus, caudate nucleus, putamen, 
globus pallidus, substantia innominata, amygdala, superior temporal 
gyrus, middle temporal gyrus, insula, thalamus, subthalamic nucleus, 
superior parietal lobule, hippocampus, posterior cingulate cortex, pre-
cuneus, inferior parietal lobule, calcarine cortex. Sections were also 
taken at the level of the midbrain (i), medulla (j), dentate nucleus 
of the cerebellum (k), and spinal cord (l). Coronal sections were 
obtained at the levels a to f. Images adapted from The Atlas of the 
Human Brain 3rd edition [21]85 Acta Neuropathol (2014) 128:81–98 
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Results
Clinical observation
For the cases presented, we refer to the original pedi-
gree from Dobyns et al. [13]. Structural imaging data 
could not be obtained due to technical difficulties related 
to the patients’ advanced stage of disease and comorbid 
conditions.
Case 1 (case II.4)
Within an hour after giving birth to her fourth child, at age 
28 the subject exhibited an oculogyric crisis and gaping 
mouth. The oculogyric crisis, a rarely observed symptom 
in rDP, resolved after a few hours but she remained unable 
to talk or swallow. She had severe upper limb dystonia and 
was unable to write. She was sent to a psychiatric hospi-
tal for several months where she was treated with electro-
convulsive therapy (eCT). It is reported that she gradually 
improved to the point where she could feed herself but the 
food had to be liquefied. She was able to walk with assis-
tance with a short shuffling gait. She remained stable until 
age 50 when she experienced severe psychological stress. 
This triggered a second episode, resulting in worsening 
over 6 months followed by a gradual deterioration over 
10 years, including becoming wheelchair-bound. exami-
nation at age 80 found her to be alert and cooperative but 
completely anarthric, requiring a touch screen communica-
tion tool. She was fed with a feeding tube due to dyspha-
gia causing aspiration. Both arms exhibited severe dysto-
nia, the left being more affected than the right with marked 
bradykinesia. She was unable to stand without assistance 
due to marked postural instability. She had cogwheel rigid-
ity, bradykinesia in the right arm and leg, but no tremor. 
Formal psychiatric and cognitive evaluations were not per-
formed due to motor and vocal limitations (Supplementary 
Table 2).
Case 2 (case II.3)
This subject is the identical twin of case 1. This patient 
had eCT for depression some time prior to onset of symp-
toms. At age 25, following the birth of a child, her left arm 
became dystonic over the course of a month and she devel-
oped a limp, though was able to walk independently. Her 
symptoms remained stable until age 42 when she experi-
enced severe psychological stress and showed a worsening 
of her gait, as well as abnormalities in her voice and her 
balance over 1–2 weeks. She could still walk unassisted but 
with a very broad-based gait and marked postural instabil-
ity. Her swallowing worsened, limiting her diet to puréed 
foods. At age 81, she remained unable to talk. Her left arm 
was rigid, and the right arm demonstrated cogwheel rigid-
ity, but no tremor. There was marked bradykinesia of finger 
movements in both hands, and the left hand had no useful 
grasp. She could no longer walk, but could rise and trans-
fer chairs with difficulty. Formal psychiatric and cognitive 
evaluations were not performed due to motor and vocal 
limitations (Supplementary Table 2).
Case 3 (case II.1)
This subject was asymptomatic but had three affected 
descendants. She had no problems with movement, but had 
leg cramps that were treated with quinine. She had con-
gestive heart failure and had been previously treated with 
digitalis (a specific inhibitor of Na+/K+-ATPase that does 
cross the blood–brain barrier to some degree). She did not 
remember any adverse effects with this medication. Her last 
examination, at age 84, demonstrated slowness in move-
ment, the absence of tremor, and normal gait. She reported 
that she did not have tremors but complained about feeling 
overall weak due to failing health.
No illness was found on psychiatric assessment. The 
patient did report that she was treated for depression fol-
lowing the death of her son (Supplementary Table 2). Cau-
tion is warranted in interpreting cognitive testing (Sup-
plementary Table 3) as poor visual acuity was noted upon 
examination. Despite her reported memory problems, 
verbal list learning was intact. Visual memory for abstract 
designs was reduced. Psychomotor processing speed was 
impaired. She displayed mild impairment on tasks of lin-
guistic and semantic verbal fluency.
Case 4 (case 11.2)
At age 45, symptoms began gradually during a self-
reported emotionally stressful time. Symptoms started in 
the right hand over 2 weeks and progressed to the right leg 
over 1 year. He reported heavy smoking and alcohol use. At 
age 53–54, he reported a worsening of symptoms follow-
ing psychological stress. He was also treated for depression 
and took digitalis for heart disease. At age 83, a neurologi-
cal examination revealed a soft, low volume speech, cog-
wheel rigidity, subtle non-focal weakness in both arms and 
legs, and a resting tremor in the right hand. Definite dys-
tonic movements in hands and feet were present.
Upon psychiatric assessment, he received diagnoses of 
psychotic disorder not otherwise specified (NOS), panic 
disorder without agoraphobia, and alcohol abuse. Symp-
toms of psychosis included paranoid delusions, thought 
insertion, thought broadcasting, and thought withdrawal 
(Supplementary Table 2).
Overall cognitive skills were estimated to be below 
average (Supplementary Table 3). Memory was generally 86   Acta Neuropathol (2014) 128:81–98
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within normal limits. Delayed recognition of a word list 
was notable for numerous false-positive errors, suggesting 
poor discrimination. executive functioning was reduced. 
Psychomotor processing speed was within normal limits, 
though performance on the motorically demanding sym-
bol digit modalities test (SDMT: written and oral) was 
impaired.
Neuropathology
A summary of case demographics is provided in Table 1. A 
detailed case-by-case description follows.
Macroscopic observation
Case 1 The brain weighed 1,144 g. No focal lesions were 
observed over the lateral or medial surface of the brain. 
Atherosclerosis was observed in the basilar and the middle 
cerebral arteries. The cerebrum was mildly and diffusely 
atrophic. The lateral ventricles were slightly enlarged. No 
changes were detected in the subcortical white matter. The 
corpus callosum measured 9 cm in the antero-posterior 
dimension; its thickness was 12 mm at the genu, 5, 9 and 
4 mm at the anterior, middle and posterior portion of the 
body, and 12 mm at the splenium. The head of the cau-
date nucleus, the putamen, and the globus pallidus were 
reduced in bulk. The thalamus was unremarkable. The 
subthalamic nucleus was thin and gray in appearance and 
measured 1 mm in its widest dimension. The amygdala 
and hippocampus were unremarkable. The rostral portion 
of the cerebellar vermis was mildly atrophic. In the mid-
brain, the substantia nigra appeared reduced in width and 
its pigmentation was uneven. In the pons, the locus coer-
uleus was well pigmented. No macroscopic abnormalities 
were observed in the spinal cord.
Case 2 The brain weight, estimated by adding the weight 
of fixed and frozen portions of the entire cerebrum, cerebel-
lum and brainstem, was 1,128 g. No focal lesions were 
observed over the lateral or medial surface of the brain. The 
status of the major vessels of the base of the brain could 
not be ascertained. Mild atrophy of the frontal and tempo-
ral lobes was noted. The lateral ventricles were unremark-
able. The white matter of the centrum semiovale and of 
the temporal lobe was reduced in bulk. Measurements of 
the corpus callosum were considered to be unreliable due 
to modifications of the specimen’s shape in transportation. 
The caudate nucleus, putamen and thalamus were unre-
markable. The globus pallidus was moderately atrophic. 
The amygdala and hippocampus were mildly atrophic. A 
macroscopic evaluation could not be carried out on the cer-
ebellum and most of the brainstem. The anterior portion of 
the substantia nigra was well pigmented. No macroscopic 
abnormalities were observed in the spinal cord.
Case 3 The brain weighed 1,076 g. No focal lesions 
were observed over the lateral or medial surface of the 
brain. Severe atherosclerosis was observed in the vertebral, 
basilar, internal carotid and middle cerebral arteries. There 
was mild atrophy of the frontal, temporal, and parietal 
lobes. The lateral ventricles were unremarkable. The cen-
trum semiovale was reduced in bulk. The corpus callosum 
thickness was 10 mm at the genu, 7 and 4 mm at the body 
anteriorly and posteriorly, and 10 mm at the splenium. The 
caudate nucleus, putamen, and globus pallidus were unre-
markable. There was a mild reduction in bulk of the thala-
mus. The subthalamic nucleus was unremarkable. The cer-
ebellar vermis appeared mildly to moderately atrophic. The 
substantia nigra and locus coeruleus were well pigmented. 
No macroscopic abnormalities were observed in the spinal 
cord.
Case 4 The brain weighed 1,226 g. No focal lesions 
were observed over the lateral or medial surface of the 
brain. Atherosclerosis was observed in the posterior and 
middle cerebral arteries. The cerebrum showed mild diffuse 
atrophy. The lateral ventricles were unremarkable. There 
was a reduction in bulk of the white matter of the frontal 
lobe. The corpus callosum measured 10 cm in its antero-
posterior length; the thickness of the corpus callosum was 
12 mm at the genu, 7, 10 and 4 mm at the anterior, middle 
and posterior portion of the body, and 13 mm at the sple-
nium. The head of the caudate nucleus, the putamen, the 
globus pallidus, and the subthalamic nucleus were mildly 
atrophic. The cerebellar vermis and dentate nucleus were 
atrophic. The substantia nigra was mildly depigmented. 
Mild, diffuse atrophy of the pons was observed. The locus 
coeruleus was well pigmented. No macroscopic abnormali-
ties were observed in the spinal cord.
Microscopic changes
A systematic evaluation led to the observation of neuro-
pathologic changes in several areas; however, they repre-
sented alterations classifiable within different disease cat-
egories. The following fundamental pathologic processes 
were detected: cerebrovascular disease, neurodegenerative 
disease of the Alzheimer type, as well as neuronal atrophy 
and loss in specific subcortical nuclei. In Table 2, we have 
summarized and separated neurodegenerative disease of the 
Alzheimer type from potentially rDP-related neuronal loss 
and gliosis.
Cerebrovascular pathology
All cases showed non-occlusive, mild to moderate athero-
sclerosis. Atherosclerosis of the basilar, posterior cerebral 
and middle cerebral arteries was found in case 1. In case 
2, arteriolosclerosis was observed in the arterioles of the 87 Acta Neuropathol (2014) 128:81–98 
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neocortex, caudate nucleus, putamen, and hippocampus. 
Atherosclerosis was observed in the vertebral, basilar, inter-
nal carotid and middle cerebral arteries of case 3; arteriolo-
sclerosis was observed in the arterioles of the neocortex. In 
case 4, atherosclerosis was found in the posterior and mid-
dle cerebral arteries; arteriolosclerosis was observed in the 
arterioles of the neocortex, caudate nucleus, putamen, and 
hippocampus.
Neurodegenerative changes of Alzheimer type
Bodian silver stain and Thioflavin S method as well as 
immunohistochemistry using antibodies to Aβ (21F12) 
and tau (AT8) revealed Alzheimer disease pathology in all 
cases. The degree of neuropathologic changes varied for 
severity and distribution (see Figs. 2, 3).
Case 1 was classified as having the following Alzhei-
mer Disease Neuropathologic Change: A3, B2, C1, inter-
mediate likelihood. Mild to moderate amyloid angiopathy 
was observed in vessels of the parenchyma of the caudate 
nucleus, putamen, superior parietal lobule, and calcarine 
cortex.
Case 2 was classified as having the following Alzhei-
mer Disease Neuropathologic Change: A3, B2, C2, inter-
mediate likelihood. Mild to moderate amyloid angiopathy 
was observed in vessels of the parenchyma of the caudate 
nucleus, putamen, thalamus, subiculum, entorhinal cortex, 
and calcarine cortex.
Case 3 was classified as having the following Alzheimer 
Disease Neuropathologic Change: A3, B2, C3, intermedi-
ate likelihood. Moderate to severe amyloid angiopathy was 
observed in vessels of the parenchyma of the temporal cor-
tex, superior parietal lobule, and calcarine cortex.
Case 4 was classified as having the following Alzheimer 
Disease Neuropathologic Change: A3, B2, C2, intermedi-
ate likelihood. Severe amyloid angiopathy was observed in 
vessels of the parenchyma of the amygdala, temporal cor-
tex, hippocampus, superior parietal lobule, calcarine cor-
tex, and cerebellum.
Immunohistochemistry for α-synuclein and TDP-43 was 
negative for all cases.
Neuronal loss and gliosis in areas affected 
by neurodegenerative changes of the Alzheimer type
loss of neurons and gliosis coexisted with AD pathology in 
several cortical and subcortical regions to varying degrees 
in each case (Table 2). In cases 1, 2, and 4, areas affected 
by neuronal loss and gliosis were the superior frontal 
gyrus, middle frontal gyrus, cingulate gyrus, superior tem-
poral gyrus, middle temporal gyrus, calcarine cortex, supe-
rior parietal lobule, subiculum, parahippocampus, entorhi-
nal cortex, thalamus, caudate nucleus, putamen, substantia 
innominata, amygdala, and hippocampus. In case 3, neu-
ronal loss and gliosis were noted in the same areas but to a 
lesser degree.
Neuronal loss and gliosis in areas free 
from neurodegenerative changes of the Alzheimer type
In the symptomatic siblings, loss of neurons and glio-
sis were observed in the globus pallidus and subthalamic 
nucleus. In the brainstem (available only from cases 1 and 
4), neuron loss and gliosis were observed in the red nucleus, 
superior colliculus, periaqueductal gray matter, pontine 
nuclei (case 1), reticular formation, dorsal motor nucleus of 
the vagus nerve, hypoglossal nucleus, and inferior olivary 
nucleus (Table 2; Fig. 4a–j). Similarly, loss of neurons and 
gliosis were observed in the same nuclei of the asympto-
matic sibling, but to a lesser degree (Fig. 4; Table 2).
In the portion of the cerebral peduncle corresponding 
to the cortico-spinal tract, a loss of myelinated fibers was 
observed in cases 1 and 4 (not shown, but similar deficits 
are shown in Fig. 6 below).
Histologic sections from the cerebellum were available 
from symptomatic cases 1 and 4 and asymptomatic case 
3. Purkinje cells, granule cells, and neurons in the den-
tate nucleus appeared reduced in number compared to the 
asymptomatic sibling (Fig. 5e–j). gliosis was present in the 
cerebellar cortex and intrafoliar white matter. Axonal and 
myelin loss was present. Swellings of axons of the Purkinje 
cells (torpedoes) were observed in the granule cell layer 
and dentate nucleus of symptomatic and asymptomatic sib-
lings. Calbindin immunohistochemistry revealed a reduc-
tion in dendritic arborization of Purkinje cells as well as 
axonal swellings (see arrow Fig. 5f) and an apparent reduc-
tion in fibers of the white matter of the cerebellar folia 
(Fig. 5c, d). There was a reduction in synaptophysin immu-
nochemical labeling in the dentate nucleus of the affected 
siblings compared to the controls (Fig. 5k–l).
A portion of the spinal cord was available from each 
case. There was a loss of fibers of the dorsal columns.
Subcortical white matter
In all four cases, axon and myelin loss was observed in 
the subcortical white matter of the middle frontal gyrus, 
inferior frontal gyrus, pre-central gyrus, post-central 
gyrus, middle temporal gyrus, and inferior temporal gyrus 
(Fig. 6). The white matter tracts affected are located in the 
areas corresponding to the following white matter tracts: 
anterior limb of the internal capsule, anterior region of 
the corona radiata, superior region of the internal capsule, 
superior frontal occipital fasciculus, superior longitudinal 
fasciculus, inferior frontal occipital fasciculus, and infe-
rior longitudinal fasciculus [15, 33]. In addition, the corpus 88   Acta Neuropathol (2014) 128:81–98
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Table 2   Neuropathologic 
assessment for each subject by 
brain area
Areas of interest: Assessment of Neuronal loss and gliosis:
Case 1C ase 2C ase 3C ase 4
Superior frontal gyrus & anterior 
cingulate gyrus 22 22
Caudate nucleus & putamen
22 11
Globus pallidus
33 13
Substantia innominata
12 21
Amygdala
11 21
Superior and middle temporal gyrus
12 11
Subthalamic nucleus
33 13
Thalamus
22 12
Hippocampus, CA1 - CA4
12 21
Hippocampus, Molecular layer
11 11
Hippocampus, Dentate Gyrus
11 10
Subiculum
11 21
Entorhinal Cortex
12 21
Posterior cingulate gyrus and 
precuneus 22 22
Superior parietal lobule
22 22
Calcarine cortex
22 12
Cerebellum, molecular layer
1n /a 11
Cerebellum, Purkinje cell layer
2n /a 12
Cerebellum, granule cell layer
1n /a 11
Cerebellum, dentate nucleus
3n /a 13
Cerebellum, white matter
2 (gliosis) n/a0 0
Midbrain, superior colliculus
1n /a 10
Midbrain, periaqueductal gray
1n /a 21
Midbrain, substantia nigra
1n /a 22
Midbrain, red nucleus
2n /a 13
Pons, locus coeruleus
0n /a 10
Pons, pontine nuclei
1n /a 10
Pons, reticular formation
1n /a 01
Medulla, dorsal motor nucleus of 
the vagus nerve
2n /a 02
Medulla, hypoglossal nucleus
2n /a 11
Medulla, inferior olivary nucleus
3n /a 13
Middle frontal gyrus
22 32
Occipital lobe
22 12
Vermis
2n /a 12
Cervical spinal cord
12 21
Thoracic spinal cord
12 11
Lumbar spinal cord
1n /a 11
Degree of neuron loss and 
gliosis in brain regions: 
none = 0, mild = 1, 
moderate = 2, severe = 3
 Areas 
of neuronal loss and gliosis, 
and no associated AD-related 
pathology (neuritic plaques, 
diffuse plaques, neurofibrillary 
tangles, neuropil threads, tau-ir 
neurons)
 
Neuritic and/or diffuse plaques 
present
 
Neuritic and/or diffuse plaques 
and neurofibrillary tangles 
present89 Acta Neuropathol (2014) 128:81–98 
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callosum of the four siblings was reduced in thickness 
(Fig. 6).
As a summary, we show a complex system of connec-
tions highlighting nuclear groups most likely involved in 
rDP (Fig. 7).
Controls
each of the four subjects carrying the I758S mutation was 
analyzed against a set of 16 control cases. The control 
cases were divided in four groups. Cases of each group had 
the same degree of Alzheimer disease and cerebrovascular 
pathology as each of the four subjects. Alzheimer changes 
involved the same cortical areas as in the I758S mutation 
carriers. The distribution of AD pathology was compara-
ble in rDP and control subjects (see Table 2 and Supple-
mentary Table 1). Unlike what was observed in the symp-
tomatic rDP patients, the globus pallidus, subthalamic 
nucleus, red nucleus, inferior olivary nucleus, Purkinje 
cell layer, granule cell layer, and dentate nucleus in indi-
viduals with Alzheimer disease and vascular disease only, 
as well as in the I758S non-symptomatic mutation carrier, 
showed a lesser degree of gliosis and cell loss compatible 
with aging changes (Supplementary Table 1). Although 
white matter changes were seen in some areas of the 16 
control cases, the extent of the comparison of white matter 
Fig. 2   Summary of neuropathologic findings from the cerebral hemi-
sphere of each case (adapted from [21]). Brains areas that are colored 
(yellow, blue, or red) demonstrate regions with neuronal loss and gli-
osis. Red represents areas that do not have neurodegenerative changes 
of the Alzheimer type. Yellow represents areas where diffuse and/or 
neuritic plaques were found. Blue represents areas where diffuse and/
or neuritic plaques and neurofibrillary tangles were present. Green 
dashed lines represent areas of the subcortical white matter where 
axon and myelin loss was found90   Acta Neuropathol (2014) 128:81–98
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pathology in rDP versus controls could not be done with 
the same anatomical accuracy.
localization of Na,K-ATPase α3 protein
Immunolabeling of the ATP1A3 gene product in sections 
of cerebellum from a control case (Fig. 8a–g), the non-
symptomatic mutation carrier (Fig. 8h), and a symptomatic 
mutation carrier (Fig. 8i) showed a pattern of expression 
very similar to that seen in previous studies of rodents (dis-
cussed below). In cerebellar cortex, brightest signal was 
from the inhibitory processes of basket cells, but many 
cerebellar cortex neurons were positive. large neurons of 
the dentate nucleus were particularly well stained. In Fig. 
8g–i, representative images are shown for control human 
tissue (age 76), for Case 3 (unaffected carrier), and Case 1 
(affected carrier) double-labeled for calbindin to highlight 
the Purkinje neurons in red. Qualitatively, the distribution 
was similar. Although the signal may appear less bright in 
the affected carrier, the epitope is sensitive to conditions 
and there is insufficient information to conclude that there 
is a difference in the enzyme’s expression or distribution.
Molecular genetic analysis
Molecular genetic analysis revealed an ATC > AgC point 
mutation predicting an amino acid substitution of isoleu-
cine to serine (I758S) in the ATP1A3 gene (Fig. 9). APOE 
results are listed in Table 1. None of the I758S mutation 
carriers had an APOE 4 allele, which is a risk factor for 
AD. See Supplementary Table 1 for control data.
Discussion
The present study, the first of its kind, focuses on the 
neuropathology of four siblings, three affected by rDP 
and one not manifesting clinical signs, all carriers of the 
Fig. 3   Summary of neuropathologic findings from the cerebellum, 
brainstem, and spinal cord of each case (adapted from [21]).  Red 
represents areas that have neuronal loss and gliosis but do not have 
neurodegenerative changes of the Alzheimer type. The green outline 
represents loss of white matter91 Acta Neuropathol (2014) 128:81–98 
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Fig. 4   Hematoxylin & eosin 
(H&e) staining from cases 1 
(a, c, e, g, i) and 3 (b, d, f, h, j). 
Note the extensive cell loss in 
the globus pallidus and subtha-
lamic nucleus of case 1 (a, c) 
compared to the same areas in 
case 3 (b, d). e, f The preserva-
tion of cells in the substantia 
nigra. There are severe neuron 
loss and gliosis in the red 
nucleus in case 1 (g) compared 
to case 3 (h). i, j The severity of 
neuron loss and the reduced size 
of neurons in the inferior oli-
vary nucleus of the affected (i) 
compared to the unaffected (j)92   Acta Neuropathol (2014) 128:81–98
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Fig. 5   Images show a compari-
son of cerebellar morphology 
in case 1 (a, c, e, g, i, k) with 
that of case 3 (b, d, f, h, j, l). 
a, b Parasagittal sections of the 
cerebellar hemisphere. Note the 
mild atrophy of the cerebellar 
cortex and pallor of the cerebel-
lar white matter. c–f Calbindin-
immunolabeled preparations. 
Note the loss of Purkinje cell 
bodies and axons in c and loss 
of dendritic arborization in e as 
compared to d and f. Note an 
axonal swelling in f (red arrow). 
Note the reduction in granule 
cells in g as compared to h. 
Note the depletion of nerve cell 
bodies in the dentate nucleus 
in i as compared to j. There is 
a reduction in synapthophysin 
immunohistochemical labeling 
in the dentate nucleus in k 
compared to l93 Acta Neuropathol (2014) 128:81–98 
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Fig. 6   Hematoxylin & eosin/luxol fast blue staining of hemispheric 
coronal sections. All four cases showed pallor of the white matter 
in the frontal and temporal regions. The white matter tracts affected 
include the internal capsule, corona radiata, superior frontal occipital 
fasciculus, superior longitudinal fasciculus, inferior frontal occipital 
fasciculus, and inferior longitudinal fasciculus. These areas are out-
lined in green94   Acta Neuropathol (2014) 128:81–98
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I758S mutation. The 4 siblings and 16 controls had the 
following pathologic changes in common: (1) a mild to 
moderate degree of cerebrovascular disease and (2) neu-
rodegenerative changes of the Alzheimer type. In the four 
siblings and controls, the Alzheimer pathology involved 
predominantly neocortex and hippocampus. All were 
classified as having mild to moderate Alzheimer disease 
changes. In addition, in the three symptomatic gene car-
riers, atrophy and severe neuronal loss were observed 
in areas free of cerebrovascular and Alzheimer disease 
pathology. These were globus pallidus, subthalamic 
nucleus, red nucleus, inferior olivary nucleus, cerebel-
lar Purkinje cell layer, granule cell layer, and dentate 
nucleus. When mild neuronal loss was observed in any 
gray matter structure, both in symptomatic gene carriers 
and controls, it was not interpreted as being significant 
for rDP. In the cortex and in areas free of Alzheimer 
pathology, immunohistochemistry for tau, α-synuclein, 
TDP-43, and ubiquitin failed to show any intracytoplas-
mic or intranuclear inclusions. In spite of the name of 
the disorder, “rapid-onset dystonia-parkinsonism,” patho-
logic changes were not detected in the substantia nigra. 
In addition, white matter tracts of the cerebrum, includ-
ing cortico-cortical, cortico-spinal, cortico-pontine, 
cortico-bulbar, thalamo-cortical, and cortico-subcortical 
fibers, showed axon and myelin losses. Furthermore, 
efferent fibers of the dentate nucleus and the intrafoliar 
white matter bundles of the cerebellum were affected, 
while in the spinal cord, the ascending sensory fibers of 
the dorsal columns were reduced. The clinicopathologic 
correlate of the dorsal column alterations remains unclear 
at this time.
The availability of the four I758S mutation carriers’ 
brains has offered the unique opportunity to study, under 
the same conditions and within a single laboratory, sib-
lings with the same mutation, similar ages at death, and 
who have undergone extensive longitudinal clinical evalu-
ations. given the rarity of rDP, it was decided to follow 
a dissection protocol aimed at obtaining half of the brain 
for future biochemical analysis. However, in so doing, 
our ability of comparing the right and left side to estab-
lish specific clinicopathological correlations and analyze 
asymmetry of anatomical lesions was lost. A significant 
challenge in this study has been the fact that the neuro-
pathologic investigation has taken place many decades 
after the clinical phenotype has manifested itself. Thus, 
the neuropathologic analysis had to take into considera-
tion co-morbidities associated with old age, namely vas-
cular pathology and neurodegeneration. The presence of 
Alzheimer pathology, including neuronal loss, has been 
an obstacle for investigating possible rDP changes in the 
cerebral cortex.
In spite of the fact that the four siblings carried the same 
genetic mutation, clinical signs of rDP developed in only 
three of them and in those three, we identified anatomi-
cal alterations. At this time, it is not clear what the inter-
action might be between genetic defect and other genetic 
and/or environmental elements for the development of the 
Fig. 7   Circuit diagram depict-
ing basal ganglia, thalamic, 
cortical, cerebellar, and 
brainstem connections. Red 
shading highlights the regions 
of the circuit where neuron 
loss and gliosis were found 
in the symptomatic siblings. 
The pathways affected are the 
pallido-thalamo-cortical loop, 
subthalamic-pallido-thalamo-
cortical loop, dentato-thalamo-
cortical loop, dentato-rubral 
loop, and dentato-olivary loop95 Acta Neuropathol (2014) 128:81–98 
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Fig. 8   Immunolabeling of Na,K-ATPase α3 subunit, the protein 
product of ATP1A3. a–c Control cerebellar cortex showing diffuse 
fluorescence for α3 (a, c, green) in the molecular layer, with more 
prominent labeling of molecular layer neurons (arrowhead, a) and 
basket cell processes surrounding the Purkinje cell bodies (arrow-
head, c). In the granular layer, fluorescence for α3 (a, c, green) lightly 
ring-labeled the granule neurons and more heavily labeled the glo-
meruli. Fluorescence in the red channel (b, c) was due to lipofuscin. 
d–f Diffuse α3 fluorescence was seen in the tissue surrounding the 
dentate nucleus, with much brighter signal in the dentate nucleus (d, 
f), particularly around large-diameter neurons (arrowhead, f). lipo-
fuscin fluorescence was also present, particularly in neuronal somas 
(e, f). The panels (g–i) show control brain (g), case 3 unaffected gene 
carrier (h), and case 1 affected gene carrier (i). Double label was for 
calbindin (red) and Na,K-ATPase α3 (green). An inset is included in 
(i) that shows the absence of fluorescence corresponding to the bright 
green fluorescence in the merged image. This indicates that the green 
fluorescence is not due to lipofuscin. Magnification bars are 50 μm 
except for the inset in (i) at 32 μm96   Acta Neuropathol (2014) 128:81–98
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full clinical phenotype. In addition, whether the cell losses 
attributed to the genetic defect are preceding the clinical 
symptoms or are occurring as a result of the movement dis-
order remains to be understood. It is of interest that among 
the three rDP-affected siblings, the twins had a very simi-
lar clinical and pathologic phenotype including age at 
onset, while the third subject’s clinical phenotype presented 
more than a decade later than the twins. In addition, the 
presence of AD changes in all four gene carriers raises the 
question as to whether the mutation in the ATP1A3 gene 
represents a risk factor for the development of Alzheimer 
disease.
To determine which anatomical structures are affected in 
the earliest stages of rDP, it would be important to obtain 
imaging in gene carriers before the onset of symptoms and 
in the early stages of rDP. Data along these lines are lim-
ited; however, recent imaging results by Whitlow and col-
leagues in rDP-affected male patients aged 26, 56, and 63 
are consistent with some of the findings of the present study 
[37]. In fact, there were statistically significant gray mat-
ter volume decreases in rDP patients compared to controls 
in the dentate nucleus. Fractional anisotropy was reduced 
among rDP patients compared to controls in the superior 
cerebellar peduncle, dentate nucleus, parahippocampal 
gyrus, thalamus, basal ganglia (caudate nucleus, putamen, 
and globus pallidus), internal and external capsules, and 
the corpus callosum. Findings of a reduction in fractional 
anisotropy in the basal ganglia and the white matter path-
ways that carry information between brain areas supports 
the neuropathologic findings presented here and supports 
further the proposed abnormal circuitry in the basal ganglia 
and cerebellum.
Detailed neuropathologic reports of other primary dys-
tonias are limited. However, nuclei implicated in rDP have 
also been implicated in other dystonias. In pallidoluysian 
atrophy, severe atrophy of the subthalamic nucleus and 
globus pallidus was reported [38]. A diffusion tensor imag-
ing (DTI) and neuropathological study in spasmodic dys-
phonia found decreased fractional anisotropy in the inter-
nal capsule and cortico-bulbar/cortico-spinal tracts, and 
water diffusivity was increased in the lentiform nucleus, 
thalamus, and cerebellum [34]. Neuropathologic exami-
nation revealed a loss of axonal density and myelin con-
tent in the internal capsule. In Meige syndrome, neuronal 
losses occurred in the substantia nigra, locus coeruleus, 
midbrain tectum, and dentate nucleus of the cerebellum 
[20]. Although there are phenotypic and genetic variations 
among the many dystonias, several key nuclei and white 
matter tracts appear to be affected.
Taking these studies together, data from imaging and 
neuropathology seem to point to the involvement of spe-
cific anatomical gray matter areas and white matter path-
ways. In this group of movement disorders, genetic and 
environmental factors may play a role in causing the clini-
cal and anatomical heterogeneity. The present data under-
score the necessity of more systematic quantitative studies 
of neuron number in areas that neuropathologic and neu-
roimaging studies seem to indicate to be most relevant in 
Fig. 9   Molecular genetic 
analysis. An ATC > AgC point 
mutation resulting in an amino 
acid substitution of isoleucine 
to serine (I758S) in the ATP1A3 
gene in the four siblings but not 
in control cases was observed. 
The K in the black box is a 
code indicating that both T 
(thymidine, normal allele) and 
G (guanidine, mutant allele) 
are present as expected for a 
dominant mutation97 Acta Neuropathol (2014) 128:81–98 
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disease pathogenesis of dystonia. Our current analysis has 
yielded some important evidence to direct future quanti-
tative studies aimed at assessing neuron number and den-
dritic morphology in brain areas identified as vulnerable in 
rDP. The current limitation of the present study is the lack 
of power resulting from the number of available cases.
Currently available data in rodents support our findings 
in view of the fact that high α3 immunostaining has been 
found in striatum, globus pallidus, subthalamic nucleus, 
substantia nigra, cerebellum, red nucleus, and the pontine 
nuclei [4, 27, 29]. In situ hybridization data for the mouse 
brain in the Allen Brain Atlas (http://www.brain-map.org) 
also show intense ATP1A3 mrNA reactivity in cell somas 
in cerebellum, dentate nucleus, red nucleus, inferior olivary 
nucleus, and other regions of interest, supporting the pos-
sibility that pathology is intrinsic to cells that express the 
mutated enzyme. Different classes of neurons can differ in 
the Na,K-ATPase isoforms they express, the expression lev-
els, and their physiological impact [1, 29], but it is not given 
that a high level of expression of ATP1A3 is the most impor-
tant factor. The presence of pathology may relate more to the 
interaction of reduced Na,K-ATPase activity with the physi-
ology of a particular cell. It is even possible that cells with 
pronounced pathology were injured by excessive excitatory 
input or a deficit of inhibitory input resulting from mutated 
Na,K-ATPase in otherwise-healthy presynaptic cells. The 
important findings are the correlation of symptoms of rDP 
with demonstrable pathology and the scarcity of pathology 
in the patient with no symptoms, and that the identified neu-
ronal populations are part of complex motor and sensory 
loops. Our data on the localization of the Na,K-ATPase α3 
protein in affected and control subjects strengthen our results 
related to the involvement of the cerebellum in rDP. Addi-
tional studies will be carried out in areas that we have identi-
fied as potentially vulnerable in rDP.
In summary, with the present study of four ATP1A3 gene 
carriers, we have identified rDP-associated pathology in 
neuronal populations in the globus pallidus, subthalamic 
nucleus, red nucleus, inferior olivary nucleus, cerebellar 
Purkinje cell layer, granule cell layer, and dentate nucleus. 
Their involvement would cause an interruption of cerebral 
and cerebellar connections that are essential for the mainte-
nance of motor control. rDP may be due to dysfunctional 
regulatory loops such as cortico-striato-pallido-thalamo-
cortical and cerebello-thalamo-cortical pathways, and addi-
tional brainstem dentatorubral-pallidal and dentato-olivary 
pathways, with abnormalities in multiple relay stations.
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